Covid-Organics as established COVID-19 prevention and treatment
01
What institutions accepted
Madagascar treated the original Covid-Organics drink as an established preventive and curative COVID-19 remedy, distributed it through national policy, and later registered CVO and CVO+ products before product-specific randomized evidence supported the breadth of the prevention and treatment claims.
02
What the evidence supports now
Laboratory inhibition can justify clinical study, but it does not establish that a drink prevents infection or improves illness in people. A CVO-specific cell-culture study found antiviral activity, yet called its selectivity index unpromising and required animal and human trials before recommending use. A later randomized trial provides relevant but much narrower evidence for CVO+ Curatif: it tested standardized artemisinin and 1,8-cineole capsules in adults with mild or moderate COVID-19, rather than the original drink or a preventive regimen, and reported 87.1% versus 75.0% success on its composite endpoint. The report analyzed 276 of 339 randomized participants per protocol, used one-tailed tests, began enrolment before registry approval, and ended below its planned analyzed sample. That result cannot retroactively validate the 2020 rollout or establish prevention by CVO products; those broader claims require product-specific, independently reproducible clinical evidence and patient-relevant outcomes.
03
Evidence for the overall belief
Open sources, locators and notes
- DocumentsHistorical beliefPlan Multisectoriel d’Urgence — COVID-19Prime Minister’s Office, Madagascar
Where in the source: Foreword, p. 4; Executive Summary, p. 6; §§2.2.1 and 2.7.6, pp. 19–20 and 25–26
The president's foreword calls Covid-Organics a preventive and curative remedy. The plan records completed school distribution, labels family packs preventive, and treats CVO as a mass-protection measure while acknowledging that the scientific basis of traditional medicines remained weakly documented.
- ContextualizesPresent correctionIn vitro efficacy of Artemisia extracts against SARS-CoV-2Virology Journal
Where in the source: Abstract; Results, Table 2; Discussion and Conclusions
The original Covid-Organics drink inhibited SARS-CoV-2 in VeroE6 cell culture, with EC50 equal to 7.73% of the raw drink and a selectivity index of 5.28. The authors called that selectivity index unpromising, said achievable human exposure remained unknown, and required animal and human trials before patient recommendations.
- ContextualizesPresent correctionEfficacy and Safety of CVO PLUS CURATIF Capsules, Malagasy Improved Traditional Medication for Treating COVID-19: A Randomized, Double-Blind, Placebo-Controlled TrialArchives of Clinical and Biomedical Research
Where in the source: pp. 817–823, especially Methods, Results, Discussion, Limitations, and Declarations
The CVO+ Curatif trial reported 87.1% success versus 75.0% with placebo (OR 2.25; p=0.011). It tested a standardized capsule richer in active compounds than the original tea, not prevention; analyzed 276 of 339 randomized participants per protocol; used one-tailed tests; began enrolment on 18 January before registry approval on 24 March 2021; and ended below the planned analyzed sample amid attrition, urgent circumstances, and lack of funding.
- SupportsPresent correctionCoronavirus disease (COVID-19): Malaria and COVID-19World Health Organization
Where in the source: 25 August 2020 Q&A, “What is WHO’s position on the use of Artemisia plant material…?”
WHO's contemporaneous assessment said evidence did not support Artemisia products or extracts as COVID-19 antivirals and found no evidence for prevention or treatment with Artemisia-based plant material. The page is preserved for reference and is no longer updated, so this evidence is used for the state of knowledge during the rollout.
- SupportsImpactPlan Multisectoriel d’Urgence — COVID-19Prime Minister’s Office, Madagascar
Where in the source: Executive Summary, p. 6; §§2.2.1.1–2.2.1.2, pp. 19–20; §2.7.6.2, p. 26
The official plan provides the card's scale figures: 270,000 pupils in a completed distribution measure, and separate programme targets of 660,600 pupils and four million households. The targets are identified as plans rather than reported completed distributions.
04
Impact
Covid-Organics moved rapidly from a presidential announcement into Madagascar's national pandemic response. The July 2020 emergency plan called it preventive and curative, recorded masks and CVO distributed to 270,000 pupils, planned CVO for 660,600 examination-class pupils, and proposed preventive family packs for four million households. The Court of Accounts later documented mass distribution through fokontany, public self-service points, schools, government offices, and hospitals, while finding no scientific study that could attribute the observed mortality pattern to CVO. Product registration also outlasted the emergency rollout: official 2025 registers listed four presentations of the original CVO and both CVO+ Curatif and CVO+ Préventif capsules.
Context
Artemisia and other plants can contain medically useful compounds. The disputed institutional step was treating composition, traditional use, early observations, or cell-culture activity as proof of prevention and treatment in people before suitable trials.
CVO, CVO+ Curatif, and CVO+ Préventif were not interchangeable products. The published randomized trial tested a higher-concentration capsule formulation for treatment of mild or moderate disease; it did not test the original tea and did not evaluate prevention.
Appearance in Madagascar's registered-medicines lists documents national regulatory status. The lists alone do not supply a clinical indication, prove efficacy, or constitute a WHO recommendation.
The emergency plan recorded masks and Covid-Organics distributed to examination-class pupils
The emergency plan's proposed reach for preventive CVO family packs, not a completed-distribution count
Official medicine registers still listed original CVO and curative and preventive CVO+ products
Historical totals and effects are presented as contextual evidence, not as universal causal claims.
Institutional episode 01
Madagascar
East Africa
Madagascar made Covid-Organics part of state pandemic policy within days of its presidential launch. It was distributed through schools and local administration, placed in the national treatment environment, and planned for household-scale preventive distribution before controlled clinical evidence existed. A later government-backed trial was a meaningful change in evidentiary method, but it examined a distinct standardized CVO+ Curatif capsule only for mild or moderate treatment. Its positive reported result did not test the original drink or prevention, and the report's attrition, per-protocol analysis, one-tailed testing, registry approval after enrolment began, and fewer evaluable participants than planned limit the inference. The Court of Accounts rejected causal claims based on observed mortality and urged systematic evaluation, yet national registers still carried original, curative, and preventive CVO products in 2025.
Institutions involved
- Presidency of the Republic of Madagascar
- Prime Minister’s Office (Primature de Madagascar)
- Ministry of Public Health of Madagascar
- Agency of Medicine of Madagascar
- Pharmalagasy
Institutional context
The presidency supplied the initial claim and distribution order. On 19 April 2020 President Andry Rajoelina announced an Artemisia-based remedy, said IMRA tests on infected people had been positive, promised clinical trials for the following week, and ordered Covid-Organics distributed when examination classes returned. The national emergency plan then described CVO as preventive and curative, embedded actual and planned distribution in education and mass-protection programmes, and proposed family packs for two-thirds of Malagasy households. The Court of Accounts found that strategic health decisions had been centralized at the presidency, that the state had adopted the remedy, and that the wholly state-owned Pharmalagasy factory received exceptional support to manufacture it. Formal evaluation followed: the government publicized a CVO+ Phase III trial in 2021 and its researchers published results in 2022. Official medicine registers nevertheless continued to list the original CVO presentations in May 2025 and both curative and preventive CVO+ capsules in July 2025.
Why this persisted
Administrative adoptionPresidential endorsement became administrative distribution, national emergency planning, a state-owned manufacturing programme, government-backed clinical research, and medicine registration. These channels gave the products preventive and therapeutic authority well beyond an experimental research setting.
How correction happened
Partially corrected2021–2022
Action: The Court of Accounts rejected a causal efficacy inference and called for systematic evaluation, while the government moved the distinct CVO+ Curatif capsule into a randomized trial.
The audit and randomized trial corrected part of the original evidentiary process: one oversight body expressly said no scientific study could tie the mortality pattern to CVO, and the later capsule was subjected to controlled testing. The correction remained incomplete because neither step withdrew the original drink's prevention and treatment claims, the trial did not test prevention or the original formulation, and official 2025 registers still listed original CVO plus products explicitly named Curatif and Préventif.
Consequences
- Distribution of masks and Covid-Organics to 270,000 examination-class pupils recorded as a completed measure
- Mass distribution through fokontany, public self-service points, schools, public administration, and hospitals
- Plans to reach 660,600 examination-class pupils and four million households with preventive CVO
- State investment in the wholly state-owned Pharmalagasy factory and continued national product registration
- Retention of the traditional remedy when the Health Ministry proposed joining COVAX in July 2020
- Public preventive and therapeutic legitimacy extending beyond the products and uses examined in a randomized trial
Evidence for this episode
12 evidence linksOpen sources, locators and notes
- DocumentsInstitutional carrierIntervention du Président de la République, S.E.M. Andry RAJOELINA du 19 avril 2020Embassy of the Republic of Madagascar in Germany
Where in the source: Sections “À propos du remède contre le Covid-19” and “Les écoles”
Official diplomatic archive of the 19 April address: the president said IMRA tests on infected people had been positive, announced clinical trials for the following week, and included distribution of Covid-Organics tea among the measures accompanying pupils' return to examination classes.
- DocumentsInstitutional carrierPlan Multisectoriel d’Urgence — COVID-19Prime Minister’s Office, Madagascar
Where in the source: Foreword, p. 4; §§2.2.1 and 2.7.6, pp. 19–20 and 25–26
The national emergency plan incorporates CVO into education and mass-protection programmes and assigns implementation through central government sectors rather than describing a private or merely experimental product.
- SupportsConsequencesPlan Multisectoriel d’Urgence — COVID-19Prime Minister’s Office, Madagascar
Where in the source: Executive Summary, p. 6; §§2.2.1.1–2.2.1.2, pp. 19–20; §2.7.6.2, p. 26
Records distribution of masks and CVO to 270,000 examination-class pupils as a measure taken; separately plans CVO for 660,600 such pupils outside confined regions and preventive family packs for four million households. The latter two figures are programme targets, not verified completion counts.
- DocumentsInstitutional carrierAudit organisationnel de la gestion de la crise sanitaire liée à la COVID-19 pour l’année 2020Cour des Comptes de Madagascar
Where in the source: §2.2.1, pp. 24–25; §3.1.3, pp. 45–46
The Court found that strategic health decisions were taken at the highest level, that the presidency displaced the Health Ministry's technical authority, and that the wholly state-owned Pharmalagasy received a new factory, imported machinery, trained staff, and exclusive raw-material supply to produce CVO.
- SupportsConsequencesAudit organisationnel de la gestion de la crise sanitaire liée à la COVID-19 pour l’année 2020Cour des Comptes de Madagascar
Where in the source: §2.2.1, p. 24; “Protocoles de traitement…”, pp. 79–80; §2.4.7, p. 90
The audit records mass sachet distribution through fokontany, public self-service drink stations, compulsory school administration with sweets, free distribution in government services, hospital equipment supplied by the presidency, and a national-treatment option. It also says the traditional remedy was retained instead of the Health Ministry's July 2020 proposal to join COVAX and that other traditional-medicine messaging was prohibited except for CVO.
- DocumentsInstitutional correctionAudit organisationnel de la gestion de la crise sanitaire liée à la COVID-19 pour l’année 2020Cour des Comptes de Madagascar
Where in the source: “Protocoles de traitement à bien communiquer et nécessitant une évaluation systématique”, pp. 79–80
The Court said no scientific study could confirm a direct, predominant correlation between the low observed mortality and the traditional remedy because it accompanied other treatments. It called for systematic protocol evaluation, stronger scientific-institution involvement, and clinical research.
- DocumentsInstitutional correctionWHO statement on the clinical trial of CVO+ remedyWorld Health Organization Regional Office for Africa
Where in the source: 5 July 2021 statement, paras. 2–8
WHO described the completed study as a Phase III trial of CVO+ capsules for mild and moderate disease, stated that recommendations require demonstrated safety, efficacy, and quality in randomized trials, and said an independent regional expert committee would examine the Malagasy data. The statement itself did not endorse efficacy.
- DocumentsInstitutional correctionEfficacy and Safety of CVO PLUS CURATIF Capsules, Malagasy Improved Traditional Medication for Treating COVID-19: A Randomized, Double-Blind, Placebo-Controlled TrialArchives of Clinical and Biomedical Research
Where in the source: pp. 817–823
Documents the government's move from observation and rollout to a randomized, double-blind, placebo-controlled trial, while also defining the narrower capsule formulation, treatment population, reported benefit, and design limitations that prevent extrapolation to the original drink or prevention.
- ContextualizesContextIn vitro efficacy of Artemisia extracts against SARS-CoV-2Virology Journal
Where in the source: Results, Table 2; Discussion and Conclusions
Establishes that the original drink had a laboratory antiviral signal, avoiding the overstatement that it had no supporting data of any kind, while drawing the crucial boundary between in-vitro activity and demonstrated benefit or prevention in patients.
- ContextualizesContextCoronavirus disease (COVID-19): Malaria and COVID-19World Health Organization
Where in the source: 25 August 2020 Q&A, Artemisia question
Provides WHO's dated evidentiary assessment during the national rollout; it is not treated as a post-2021 review of the later CVO-specific cell study or CVO+ capsule trial.
- DocumentsMechanismListe des médicaments enregistrés à Madagascar du 02/05/2025Agency of Medicine of Madagascar
Where in the source: Product codes 40367–40370
The 2 May 2025 official register lists original CovidOrganics/Tambavy as 33 cl and one-litre solutions, tea bags, and 16.5 g powder sachets manufactured by IMRA. Registration documents regulatory continuity but does not itself establish a clinical indication or efficacy.
- DocumentsInstitutional correctionListe des médicaments enregistrés à Madagascar du 14/07/2025Agency of Medicine of Madagascar
Where in the source: Product codes 40640 and 40404
The 14 July 2025 official register lists both CVO Plus Curatif and CVO Plus Préventif capsules from CNARP and Pharmalagasy. The prevention-labelled registration is especially material because the published randomized trial evaluated treatment of mild or moderate disease, not prevention.
Source registryEach source is registered once and can carry several precise evidence relationships.9 sources
- 01Plan Multisectoriel d’Urgence — COVID-19Prime Minister’s Office, Madagascar4 evidence links
- 02Audit organisationnel de la gestion de la crise sanitaire liée à la COVID-19 pour l’année 2020Cour des Comptes de Madagascar3 evidence links
- 03WHO statement on the clinical trial of CVO+ remedyWorld Health Organization Regional Office for Africa1 evidence link
- 04Intervention du Président de la République, S.E.M. Andry RAJOELINA du 19 avril 2020Embassy of the Republic of Madagascar in Germany1 evidence link
- 052 evidence links
- 062 evidence links
- 07Coronavirus disease (COVID-19): Malaria and COVID-19World Health Organization2 evidence links
- 08Liste des médicaments enregistrés à Madagascar du 02/05/2025Agency of Medicine of Madagascar1 evidence link
- 09Liste des médicaments enregistrés à Madagascar du 14/07/2025Agency of Medicine of Madagascar1 evidence link